6/14/2013

The Supreme Court's decision Thursday that naturally occurring human genes can't be patented could have broad implications for the pharmaceutical, biotech and gene-testing industries. Critics said the ruling would not only hurt Myriad Genetics, but also the bottom line of companies that sell genetic tests. It could also discourage investment in genetic sequencing research. "The Supreme Court's decision today represents a troubling departure from decades of judicial and Patent and Trademark Office precedent," BIO President and CEO Jim Greenwood said.

Related Summaries